145 related articles for article (PubMed ID: 31977485)
21. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?
Hentschel M; Rottenburger C; Boedeker CC; Neumann HP; Brink I
Clin Nucl Med; 2012 Feb; 37(2):e24-9. PubMed ID: 22228360
[TBL] [Abstract][Full Text] [Related]
22. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
23. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
[TBL] [Abstract][Full Text] [Related]
24. Radioguided hepatic resection with
López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
[TBL] [Abstract][Full Text] [Related]
25. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer.
Soussan M; Nataf V; Kerrou K; Grahek D; Pascal O; Talbot JN; Montravers F
Nucl Med Commun; 2012 Jul; 33(7):775-9. PubMed ID: 22546877
[TBL] [Abstract][Full Text] [Related]
26. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
27. Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?
Castinetti F; Taïeb D
Thyroid; 2021 Feb; 31(2):151-155. PubMed ID: 33191866
[TBL] [Abstract][Full Text] [Related]
28. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract][Full Text] [Related]
29. Early acquisition of [
Kjærulff MLG; Dias AH; Iversen P; Gormsen LC; Hjorthaug K
Eur J Hybrid Imaging; 2022 Aug; 6(1):20. PubMed ID: 36002696
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma.
Rodríguez-Bel L; Sabaté-Llobera A; Rossi-Seoane S; Reynés-Llompart G; Vercher Conejero JL; Cos-Domingo M; Moreno-Llorente P; Pérez-Maraver M; Cortés-Romera M; Gámez Cenzano C
Clin Nucl Med; 2019 Mar; 44(3):194-200. PubMed ID: 30562193
[TBL] [Abstract][Full Text] [Related]
32. Early
Leroy-Freschini B; Amodru V; Addeo P; Sebag F; Vix M; Brunaud L; Klein M; Bahougne T; Bachellier P; Castinetti F; Goichot B; Chevalier E; Taieb D; Imperiale A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):686-695. PubMed ID: 30617961
[TBL] [Abstract][Full Text] [Related]
33. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT.
Kirchner J; Sawicki LM; Suntharalingam S; Grueneisen J; Ruhlmann V; Aktas B; Deuschl C; Herrmann K; Antoch G; Forsting M; Umutlu L
PLoS One; 2017; 12(2):e0172553. PubMed ID: 28225831
[TBL] [Abstract][Full Text] [Related]
34. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
35. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
36. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.
Asa S; Sonmezoglu K; Uslu-Besli L; Sahin OE; Karayel E; Pehlivanoglu H; Sager S; Kabasakal L; Ocak M; Sayman HB
Ann Nucl Med; 2021 Aug; 35(8):900-915. PubMed ID: 33993425
[TBL] [Abstract][Full Text] [Related]
38. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.
Treglia G; Castaldi P; Villani MF; Perotti G; Filice A; Ambrosini V; Cremonini N; Versari A; Fanti S; Giordano A; Rufini V
Recent Results Cancer Res; 2013; 194():385-93. PubMed ID: 22918771
[TBL] [Abstract][Full Text] [Related]
39. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?
Binse I; Poeppel TD; Ruhlmann M; Gomez B; Umutlu L; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1011-7. PubMed ID: 26686334
[TBL] [Abstract][Full Text] [Related]
40. Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions.
Schierz JH; Opfermann T; Steenbeck J; Lopatta E; Settmacher U; Stallmach A; Marlowe RJ; Freesmeyer M
J Nucl Med; 2013 Jun; 54(6):848-54. PubMed ID: 23528383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]